27.07.2011 • News

Strong Franc hits Lonza's Profit

Lonza reported Wednesday that its first-half profit fell 28% to 97 million Swiss francs or 1.89 francs per share from 135 million francs or 2.61 francs a year ago.

Core profit, which excluded items, dropped 23% to 107 million francs or 2.08 francs per share.

For the first half, sales fell 8.3% to 1.19 billion francs from 1.30 billion francs last year, due to strong negative currency exchange rate impacts. At constant exchange rate, revenue grew 4.8% with strong performance in Biological Custom Manufacturing and Development Services. Looking ahead, the company said it remains on track to deliver continued growth for the full year, despite ongoing market volatility combined with macro-economic uncertainties.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.